| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Konings, Renske Van Gool, Matthijs H. Bard, Martin P. L. Zwijnenburg, Anthonie Titulaer, Bart M. Aukema, Tjeerd S. Valdés Olmos, Renato A. Sikorska, Karolina Klomp, Houke M. Rijna, Herman |
| Description |
Country affiliation: Netherlands Author Affiliation: Konings R ( Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands.); van Gool MH ( Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. m.v.gool@nki.nl.); Bard MP ( Department of Pulmonology, Spaarne Gasthuis, Haarlem, The Netherlands.); Zwijnenburg A ( Department of Nuclear Medicine, Spaarne Gasthuis, Haarlem, The Netherlands.); Titulaer BM ( Department of Nuclear Medicine, Spaarne Gasthuis, Haarlem, The Netherlands.); Aukema TS ( Department of Nuclear Medicine, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.); Valdés Olmos RA ( Department of Nuclear Medicine, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.); Sikorska K ( Department of Biometrics, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.); Klomp HM ( Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.); Rijna H ( Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands.) |
| Abstract |
INTRODUCTION: In this study we evaluated the value of pre-operative glucose corrected maximum standard uptake value (GC-SUVmax) as prognostic factor in patients with early stage non-small cell lung cancer (NSCLC) after complete surgical resection. METHODS: This study was designed as a retrospectively evaluated single center study with prospective data registry. Inclusion criteria were: histologically proven stage I NSCLC, 18F-FDG-PET/CT scan prior to surgery, complete resection (R0) and follow up in our outpatient department. Exclusion criteria were: history of malignancy other than NSCLC, diabetes and (neo) adjuvant therapy. Follow up period was 5 years. RESULTS: Between 2006 and 2008 a total of 33 patients (16 males, 17 females) met the inclusion criteria. SUVmax and GC-SUVmax were strongly correlated (Spearman's ρ = 0.97). Five-year overall survival (OS) rate was 70 % (95 % CI = 56-87 %). Patients who died within 5 years of follow up had significantly higher pre-operative GC-SUVmax (median = 10.6, IQR = 8.3-14.4) than patients who were alive at 5-year follow up (median = 6.4, IQR = 3.0-9.8), p = 0.04. SUVmax showed similar differences: 10.4 (8-12.9) vs. 6.6 (3.0-8.8), p = 0.047. The area under the receiver-operating characteristic (ROC) curve at 5 years was 0.70 (95 % CI = 0.50-0.90) for GC-SUVmax and 0.71 (95 % CI = 0.51-0.91) for SUVmax (p = 0.75). CONCLUSION: Pre-operative FDG tumor uptake in patients with NSCLC is predictive for survival after complete surgical resection. GC-SUVmax, as an additional value to SUVmax, may better approach competitive inhibition of FDG and glucose in tumors, however, in this study this potential advantage, if any, was very small. |
| File Format |
HTM / HTML |
| ISSN |
09147187 |
| Issue Number |
5 |
| Journal |
Annals of Nuclear Medicine |
| Volume Number |
30 |
| e-ISSN |
18646433 |
| Language |
English |
| Publisher |
Springer |
| Publisher Date |
2016-06-01 |
| Publisher Place |
Japan |
| Access Restriction |
One Nation One Subscription (ONOS) |
| Subject Keyword |
Discipline Nuclear Medicine |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Radiology, Nuclear Medicine and Imaging |
